mTOR inhibitors

Studies of mTOR inhibitors in people

52 studies gave mTOR inhibitors to people and measured what changed

What changedDesignPeopleSource

up: Increases investigator's Global Assessment success72.4% versus 33.3%; adjusted relative risk 1.949 (95% CI 1.153–3.294)

down: Decreases approximate protrusion volume−61.556 units; P < .001

Randomized trial12 weeks65 peopleHyperplastic rosaceaJournal of the American Academy of Dermatology, Nov 10, 2026

up: Increases total cholesterolWeek 18 total cholesterol: 236.0 versus 219.6 mg/dl; LDL cholesterol: 151.7 versus 136.8 mg/dl; triglycerides: 159.4 versus 133.2 mg/dl

up: Increases C-reactive protein

down: Decreases hemoglobin-related parameters

Randomized trial18 weeks63 peopleALSFrontiers in pharmacology, Oct 30, 2026

up: Improves clinical response3 months: 4/5 (80%; 95% CI 28–99); 12 months: 3/4 evaluable (75%; 95% CI 19–99)

Treated cohort3 and 12 months5 peopleAdd-on treatment for active refractory iMCD-TAFROFrontiers in immunology, Oct 16, 2026

up: Increases cerebral blood flow

no change: Has no effect on cerebral blood flow

Trial4-week23 peopleaged 45 to 65 yearsCognitively normal adults aged 45 to 65 yearsJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Sep 10, 2026

up: Improves exercise-induced insulin sensitivity53% on average versus placebo

Randomized trialMenbioRxiv, Sep 2, 2026

up: Improves FEV1

up: Improves health-related quality of life

Trial24 weeks48 peopleWomen42(37-49) year oldSirolimus-naive LAM patientsAmerican Journal of Respiratory and Critical Care Medicine, May 1, 2026

no change: Has no effect on 30-s chair stand test−2.13 repetitions, 95% CI −4.61 to 0.34

down: Impairs 30-s chair stand test−3.44 repetitions, 95% CI −5.86 to −0.99

no change: Has no effect on 6-minute walk distance−4.87 m, 95% CI −28.97 to 19.71

Randomized trial13 weeks40 peopleBoth65–85 yearsCommunity‐dwelling adults aged 65–85 yearsJournal of cachexia, sarcopenia and muscle, Apr 1, 2026

down: Decreases major adverse limb eventsrisk difference -4.9 percentage points (95% CI -8.5 to -1.3); 8.8% vs 15.0%

no change: Has no effect on mortalityrisk difference -1.0 percentage points (95% CI -4.6 to 2.7); P = 0.67

Randomized trial1 year1,252 peopleBothmedian 75 yearsOlder adults; primary composite of unplanned major amputation or target-lesion revascularization for critical limb ischemia within 1 yearThe New England journal of medicine, Mar 30, 2026

up: Increases cardiac output

up: Increases late diastolic (A-wave) kinetic energy

up: Increases left retinal ganglion cell layer thickness

Trial26 weeks14 peopleEarly-stage Alzheimer's disease; uncontrolled pre-post comparisonmedRxiv, Mar 12, 2026

no change: Has no effect on primary vessel patency73.9% versus 74.9%; risk difference -1.0 percentage points (95% CI -9.6 to 7.6); noninferiority not statistically robust

no change: Has no effect on freedom from clinically driven target vessel revascularization, major target limb amputation, and device- or procedure-related death90.5% versus 92.7%; risk difference -2.2 percentage points (95% CI -7.7 to 3.2); Pnoninferiority = 0.003

Randomized trial12 months482 peopleBoth68.0 ± 8.9 yearsOlder adults; symptomatic femoropopliteal artery diseaseJournal of the American College of Cardiology, Feb 18, 2026

up: Improves progression-free survival11.8 months vs 1.8 months

no change: Has no effect on overall survival38.3 vs 38.2 months

Randomized trial30 peopleMetastatic GEP-NEN or LCNEC after first-line chemotherapyThe oncologist, Jan 23, 2026

down: Decreases DNA lesional burden

up: Increases cell survival3‐fold greater cell survival with over 60% cells still viable 24 h after zeocin treatment

Trial4 monthsmaleOlder male volunteersAging cell, Jan 12, 2026

down: Decreases plasma cytokines

up: Increases cerebral blood flow

up: Increases plasma cytokines

Trial4-12 weeks9 peopleBothmiddle-agedMidlife adults; Older adults; in APOE4 carriers in the prevention trialGSA 2025 abstract, Dec 31, 2025

no change: Has no effect on cerebral glucose metabolism

up: Increases cerebral glucose metabolism

up: Increases CSF total tau, neurofilament light and amyloid-β 40

Trial26 weeks14 peopleEarly-stage Alzheimer's disease, primary AD-signature regionsmedRxiv, Dec 9, 2025

up: Improves pregnancy50.0% vs. 28.2%, RR 1.77, 95% CI 0.98 to 3.19

up: Increases blastocyst qualitymedian 1.0 vs. 0

Trial21–28 days100 peoplewomenapproximately 36 yearsInfertile women who had a history of more than one IVF cycle failureCell reports. Medicine, Oct 27, 2025

up: Improves cardiac function

up: Improves endothelial function

up: Increases grip strength

Trial8 weeks6 people6 male subjects74.7 ± 2.4 yr.Male subjects (ages 70–76) who were in good overall health and devoid of any active cardiovascular problemsGeroScience, Sep 19, 2025

no change: Has no effect on rapamycin level

no change: Has no effect on cognitive function

up: Increases systolic blood pressure127.8 ± 19.0 vs 138.2 ± 22.1 mmHg

Trialeight-week10 people60% femalemean age 74 ± 4 yearsOlder adults with a clinical diagnosis of MCI or mild dementia due to ADCommunications medicine, May 20, 2025

no change: Has no effect on visceral adiposity

up: Improves lean tissue massOR = 28, 95% CI = 2.42–323.7

down: Decreases painmd = 8.071 (95% CI = 3.044–13.098)

Randomized trial48 weeks114 people35.1% of participants overall (n = 40)aged 50–85 yearsHealthy individuals aged 50–85 yearsAging, Apr 4, 2025

up: Improves cerebral blood flow>15%

up: Increases short-chain fatty acids

no change: Has no effect on Tau

Trial4 weeks23 people45–65 yearsCognitively normal adults without diabetesResearch square, Mar 19, 2025

no change: Has no effect on adverse events

no change: Has no effect on visceral adiposityη p2=0.001, p=0.942

up: Increases lean tissue massε2=0.202, p=0.013

Randomized trial48 weeksWomenWomen using 10 mg weeklymedRxiv, Aug 22, 2024

no change: Has no effect on oocyte maturation rate46.5–60.0% maturation across five groups; P = 0.30

no change: Has no effect on euploidy rate37.8–47.8% euploidy across five groups; P = 0.87

Randomized trial24 h201 peopleWomen>38 yearsMidlife adults; rescue IVM of GV oocytes from women >38 yearsMolecular human reproduction, Jan 5, 2024

down: Decreases mammary stem cell activity

down: Decreases luminal progenitor self-renewal capacity

down: Decreases luminal cell population

Trial5–7 days27 peoplewomenWomen of at least 18 years of age with confirmed menopausal status diagnosed with DCIS, LCIS, ADH, or ALH lesions scheduled for mastectomy or lumpectomyBreast cancer research : BCR, Oct 30, 2023

up: Improves clinical symptoms

Treated cohort4 peopleChinese APDS2 patients from 4 unrelated familiesResearch Square, Apr 19, 2023

up: Increases memory CD4+ and CD8+ T cells

up: Increases effector memory CD4+ T cells

down: Decreases MCP-1

Trial6 monthsTransfusion-dependent β-thalassemia patientsJournal of cellular and molecular medicine, Jan 10, 2023

no change: Has no effect on central subfield thickness-53.9 μm, p = 0.28

no change: Has no effect on visual acuity2.5 vs 0.8 letters, p = 0.42

Randomized trial36 weeks20 peoplePatients with persistent, exudative AMDInternational journal of retina and vitreous, Jan 5, 2023

up: Increases seroconversion56% vs 13%

up: Increases SARS-CoV-2 IgG antibodies160 AU/mL (0–142) vs 0 AU/mL (0–0)

no change: Has no effect on cellular response44% vs 50%

Randomized trial28 d32 people12 (38%) were female72 ± 4 yElderly (≥65 y), de novo KTRsTransplantation, May 11, 2022

down: Decreases spleen/lymph node size

Treated cohort1 personIn a GIMAP5-deficient patientbioRxiv (Cold Spring Harbor Laboratory), Feb 23, 2021

down: Decreases central subfield thickness-40 μm in sirolimus group vs +20 μm in anti-VEGF group

no change: Has no effect on visual acuity

Randomized trialsix months20 peoplePatient cohortsInternational journal of retina and vitreous, Feb 16, 2021

down: Decreases p16INK4a

up: Increases collagen VII

up: Improves skin appearance

Randomized trial8 months36 peoplegreater than 40 years of ageAdults greater than 40 years of age with no history of diabetes or hypercholesterolemiaGeroScience, Nov 25, 2019

down: Decreases clinical symptomssubstantial improvement (not quantified in abstract)

Treated cohort4 peopleFour rapamycin-treated patients with APDS1Journal of clinical immunology, Nov 29, 2018

down: Lowers the risk of infectionP = 0.001

up: Increases antiviral gene expression

up: Improves influenza vaccination response

Randomized trial6 weeks264 peopleelderlyOlder adults; elderly subjects, low-dose combination given for 6 weeksScience translational medicine, Jul 11, 2018

no change: Has no effect on geographic atrophy growth ratemean growth 4.94 vs 5.72 mm2 at month 24 (sirolimus vs sham); P=0.33

no change: Has no effect on best-corrected visual acuity change

up: Increases sterile endophthalmitis3 participants in the sirolimus group

Randomized trial24 months52 peoplemean age 79 yearsOlder adults; monthly intravitreal injection in geographic atrophy versus shamOphthalmology. Retina, May 1, 2018

down: Decreases hemoglobin

up: Increases regulatory T cells

no change: Has no effect on cognitive function

Randomized trial8 weeks28 people70-95 years; mean age 80.5Healthy older personsExperimental gerontology, Feb 3, 2018

no change: Has no effect on everolimus pharmacokinetic parameters across timepointsCtrough 4.7 ± 2.5 ng/mL; AUC0-12h 106 ± 51 ng/h per mL

Trialfirst 6 months after transplantation16 peopleBothmean 64 yearsOlder adults; with steady-state tacrolimusTransplantation, Sep 1, 2017

down: Decreases seizure frequencymedian reduction 39.6% high exposure and 29.3% low exposure vs 14.9% placebo

up: Increases seizure response rate40.0% vs 15.1% with placebo

up: Increases grade 3 or 4 adverse events24% high exposure, 18% low exposure, 11% placebo

Randomized trial12-week maintenance period366 people2-65 yearsAdjunctive therapy in tuberous sclerosis complex with treatment-resistant focal-onset seizuresLancet (London, England), Sep 6, 2016

down: Decreases DNA damage

Trialone year17 peopleSwitch from calcineurin inhibitors, one year after switchEuropean journal of cell biology, Jun 15, 2016

down: Decreases senescence-associated beta-galactosidase2.2% vs 3.6%; p=0.18

no change: Has no effect on frailty

Trial12 weeks13 peopleBothMedian age 73.9±7.5 yearsOlder adults; older adults with coronary artery disease undergoing cardiac rehabilitationThe Journal of frailty & aging, Jan 1, 2016

down: Lowers the risk of disease progression or deathHR 0.48, 95% CI 0.35–0.67

up: Improves progression-free survival11.0 vs 3.9 months

down: Lowers the risk of mortalityHR 0.64, 95% CI 0.40–1.05

Randomized trial302 peopleadults aged ≥18 yearsPatients with advanced, nonfunctional NET of lung or GI originLancet (London, England), Dec 17, 2015

no change: Has no effect on progression-free survivalHR 0.89, 95% CI 0.73-1.08; median 14.95 vs 14.49 months

up: Increases progression-free survivalmedian 20.27 vs 13.08 months (+7.2 months); HR 0.66

up: Increases stomatitis67% vs 32% of patients

Randomized trialmedian follow-up 41·3 months (IQR 35·4-46·6)719 people18 years or olderFull study populationThe Lancet. Oncology, Jun 16, 2015

up: Improves response to influenza vaccinationabout 20% enhancement

down: Decreases PD-1 expression on T lymphocytes

Randomized trialelderlyOlder adults; in elderly volunteersScience translational medicine, Dec 24, 2014